glp-1 triple agonist Agonism Based Therapies for Obesity Incretin-based therapies in MASLD/MASH: from
Description
Strong associations between subsequent reductions in body weight, HbA1c, and visceral fat and reductions in inflammatory biomarkers were found in several of the trials included in our evaluation (28, 35, 51, 52)
34 , 35 However, the controversy surrounding the possible benefits of GIPR agonism stems from two main observations: its impaired insulinotropic effects, 36 , 37 and the prevention of weight gain by suppression of endogenous GIP-induced adipogenesis, 38 , 39 However, these seemingly discouraging observations have been questioned by the finding of the central anorexic effects of GIP, 4042 and benefits of the GLP-1R/GIPR dual agonist LY3298176 (tirzepatide) in diabetic and overweight individuals
The National Institute of Drug Abuse (NIDA) announced they are sponsoring a clinical trial testing whether Tirzepatide could effectively treat cannabis use disorder
The co-occurrence of depression and obesity
212 LiHCaoLRenYJiangYXieWLiD
GIP(3-30)NH 2 demonstrated an inhibition of the GIP-potentiated glucose-stimulated insulin secretion by 82%
